Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

LESSONS LEARNED. Pharmacokinetic results underscore that the vorolanib (X‐82) study design was successful without the need for further dose escalation beyond 400 mg once daily (q.d.). Therefore, the recommended dose of X‐82 as a single agent in patients with advanced cancer is 400 mg q.d. BACKGROUND...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Bendell, Johanna C., Patel, Manish R., Moore, Kathleen N., Chua, Cynthia C., Arkenau, Hendrik‐Tobias, Dukart, Gary, Harrow, Kim, Liang, Chris
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2018
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459237/
https://ncbi.nlm.nih.gov/pubmed/30478190
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0740
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados